Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive ...

Sarepta Therapeutics (NASDAQ:SRPT) presented preliminary clinical data from ongoing phase I/II studies of two investigational ...

The FDA has granted Fast Track designation to BW-20805, an investigational small interfering RNA therapy for hereditary angioedema.

Sarepta Therapeutics (NASDAQ:SRPT) stock is up approximately 20% in early trading on Wednesday after the company released its ...

Shares of Sarepta Therapeutics SRPT rose 35% on Wednesday after the company announced early clinical data on two experimental ...

Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral ...

Sarepta Therapeutics (SRPT) shares soared 35% in the last trading session to close at $23.77. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six ...

The FDA awards Fast Track designation to BW-20805 for hereditary angioedema, a therapy designed to reduce attacks through PKK ...

Interna Therapeutics, a clinical-stage biopharmaceutical company announced today that it has signed an agreement with the University of Oxford to conduct a Phase IIa human challenge trial evaluating ...

Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two ...